Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Mts1 CRISPR/Cas9 KO Plasmid (h): sc-401774
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Mts1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Mts1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Mts1 Antibody (A-7): sc-377059
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Mts1 CRISPR/Cas9 KO Plasmid (h) | sc-401774 | 20 µg | $397.00 |
Overview
S100A4 encodes Mts1, a Ca2+-binding S100 family protein that functions as a regulator of cytoskeletal dynamics, cell motility, and intercellular signaling. Mts1 interacts with targets such as non-muscle myosin II and components of actin remodeling to influence adhesion turnover, migration, and extracellular matrix responses. It is expressed in multiple cell types including fibroblasts and immune populations and is often used as a marker of activated stromal programs. Dysregulated S100A4 expression has been linked to inflammatory remodeling and tumor-associated invasion/metastatic phenotypes, making it relevant for studies of tissue fibrosis, immune cell trafficking, and cancer cell dissemination.
Mts1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the S100A4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the S100A4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the S100A4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Mts1 protein expression.
This CRISPR knockout system enables efficient generation of S100A4-deficient cell models for investigation of Mts1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting S100A4 exon(s) critical for Mts1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple S100A4 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Mts1 CRISPR/Cas9 KO Plasmid (h) and Mts1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the S100A4 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Mts1 HDR Plasmid (h) and Mts1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by S100A4 homology arms to support homology-directed repair at defined S100A4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.